Taro Pharmaceuticals just announced that they have partnered with BioPlus as the exclusive dispenser of the new specialty generic medication deferiprone.
Deferiprone (the generic form of Ferriprox®) treats transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Thalassemia is a genetic-based group of blood disorders that can cause anemia due to changes in hemoglobin.
Although thalassemia syndromes are considered rare in the United States, they are still the most common autosomal recessive disorders. These syndromes affect an estimated 1 in 100,000 people. Even with treatment, these syndromes can be associated with the complication of iron overload, due to frequent blood transfusions.
If you’re looking for a generic iron chelator option for your patients with thalassemia syndromes, know that deferiprone is now here and available from BioPlus. Thank you, Taro Pharmaceuticals for choosing BioPlus as the exclusive distributor of this medication. And, as always, you can count on BioPlus for the specialty pharmacy medications your patients need.
Related Posts
Pemphigus: Learn This Treatable Skin Disorder
Pemphigus vulgaris is a rare group of autoimmune disorders that cause blisters and...
BioPlus Acquires California-Based Santa Barbara Specialty Pharmacy
BioPlus Infusion Pharmacy, the first and only infusion pharmacy with individualized, high-touch...
BioPlus Launches California-Based Specialty Pharmacy to Better Serve Local Communities
California patients and providers now have greater access to the ‘Power of 2’ promise as BioPlus...
September: Blood Cancer Awareness Month
Blood Cancer Awareness Month comes each September, as The Leukemia & Lymphoma Society aims to...